The following case profiles highlight how SearchLight DNA® provides greater clarity about the behavior of your patient’s tumor and delivers the most up-to-date information on treatment options.
SearchLight DNA Testing Revealed Treatment Strategies for Aggressive Oteosarcoma: Aubie
SearchLight DNA testing revealed 7 mutation biomarkers and two therapeutic options, including a PALB2 mutation that can predict sensitivity to platinum-based chemotherapy combined with PARP inhibition.
Olaparib (PARP inhibitor) and carboplatin were implemented as a first-line therapeutic approach resulting in remission and far exceeded the expected survival seen with a carboplatin regimen alone.
SearchLight DNA analysis is especially helpful to guide treatment strategies with aggressive cancers such as osteosarcoma
SearchLight DNA® Provided Novel and Encouraging Treatment: Tenney
Tenney, a handsome, vibrant 8-year-old Boston Terrier, had a diffuse liver mass that was cytologically diagnosed as a carcinoma. He was suffering from nausea, depression, lethargy, elevated liver enzymes and anemia, and was doing poorly.
A SearchLight DNA test revealed 9 mutations and two lines of targeted therapy options.
Treatment with the combination of carboplatin and olaparib has stabilized Tenney’s disease, normalized his coagulation and liver function, and significantly improved his quality of life.
In Tenney’s case, SearchLight DNA provided critical therapeutic insights based on the identification of multiple druggable mutations. This led to the use of a treatment that has successfully controlled his disease.
SearchLight DNA® Reveals BRAF Point Mutation: Remmy
Remmy, a vibrant young Doberman Pinscher, had a mass along the hard palate that was histologically identified as a poorly differentiated neoplasm.
A SearchLight DNA test revealed a BRAF point mutation, suggesting sensitivity to multiple targeted therapies including trametinib.
In Remmy’s case, SearchLight DNA was able to give a therapeutic indication based on a mutation identified within the tumor, even though the mutation is usually associated with other tumor types.
Remmy’s tumor experienced significant shrinkage with trametinib, and Remmy did not have any side effects associated with this drug.
A 10-year-old golden retriever named Nira was diagnosed with histiocytic sarcoma. After completing an initial course of radiation therapy, medical treatment with cobimetinib was started based on literature suggesting the tumor could bear KRAS and PTPN11 mutations, which are associated with response to cobimetinib.
A SearchLight DNA test revealed the absence of KRAS or PTPN11 mutations along with the presence of a mutation that suggested cobimetinib resistance. The treatment plan was switched to only radiation therapy and sirolimus.
In Nira’s case, SearchLight DNA provided valuable data that informed her treatment plan.
